Meeting
2023 ASCO Genitourinary Cancers Symposium
Effect of early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting on cancer-specific survival in metastatic castrate-resistant prostate cancer.
Authors
Kelly Lehner
Mayo Clinic, Rochester, MN
Kelly Lehner , Mohamed E. Ahmed , Raevti Bole , Jack R. Andrews , Rimki Haloi , Michael S. Bold , Ayse T. Kendi , R. Jeffrey Karnes , Eugene D. Kwon , Alan Haruo Bryce
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 189)
DOI
10.1200/JCO.2023.41.6_suppl.189
Abstract #
189
Poster Bd #
F2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
First Author: Christophe Massard
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai